BR112023021840A2 - Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco - Google Patents
Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-troncoInfo
- Publication number
- BR112023021840A2 BR112023021840A2 BR112023021840A BR112023021840A BR112023021840A2 BR 112023021840 A2 BR112023021840 A2 BR 112023021840A2 BR 112023021840 A BR112023021840 A BR 112023021840A BR 112023021840 A BR112023021840 A BR 112023021840A BR 112023021840 A2 BR112023021840 A2 BR 112023021840A2
- Authority
- BR
- Brazil
- Prior art keywords
- ards
- stem cells
- acute respiratory
- precoursor
- treating acute
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 title 1
- 230000005801 respiratory difficulty Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901214A AU2021901214A0 (en) | 2021-04-23 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021902180A AU2021902180A0 (en) | 2021-07-15 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2022900260A AU2022900260A0 (en) | 2022-02-09 | Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells | |
| AU2022900372A AU2022900372A0 (en) | 2022-02-18 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| PCT/IB2022/053763 WO2022224207A1 (en) | 2021-04-23 | 2022-04-22 | Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021840A2 true BR112023021840A2 (pt) | 2024-02-06 |
Family
ID=81585202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021840A BR112023021840A2 (pt) | 2021-04-23 | 2022-04-22 | Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco |
| BR112023021825A BR112023021825A2 (pt) | 2021-04-23 | 2022-04-22 | Método para tratar síndrome da angústia respiratória aguda (sara) em pacientes específicos utilizando precursores de linhagem mesenquimal ou células tronco |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021825A BR112023021825A2 (pt) | 2021-04-23 | 2022-04-22 | Método para tratar síndrome da angústia respiratória aguda (sara) em pacientes específicos utilizando precursores de linhagem mesenquimal ou células tronco |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240207323A1 (https=) |
| EP (2) | EP4326294A1 (https=) |
| JP (2) | JP2024516172A (https=) |
| KR (2) | KR20240001172A (https=) |
| AU (2) | AU2022261504A1 (https=) |
| BR (2) | BR112023021840A2 (https=) |
| CA (2) | CA3216129A1 (https=) |
| WO (2) | WO2022224206A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087868A1 (en) | 2010-10-08 | 2012-04-12 | Gabriele Todd | Nanoparticle-loaded cells |
| SG11202004680UA (en) | 2017-11-22 | 2020-06-29 | Mesoblast Int Sarl | Cellular compositions and methods of treatment i |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| BR112021024310A2 (pt) * | 2019-06-05 | 2022-02-15 | Univ Emory | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus |
-
2022
- 2022-04-22 BR BR112023021840A patent/BR112023021840A2/pt unknown
- 2022-04-22 AU AU2022261504A patent/AU2022261504A1/en active Pending
- 2022-04-22 JP JP2023564582A patent/JP2024516172A/ja active Pending
- 2022-04-22 US US18/556,845 patent/US20240207323A1/en active Pending
- 2022-04-22 WO PCT/IB2022/053762 patent/WO2022224206A1/en not_active Ceased
- 2022-04-22 CA CA3216129A patent/CA3216129A1/en active Pending
- 2022-04-22 AU AU2022260822A patent/AU2022260822A1/en active Pending
- 2022-04-22 BR BR112023021825A patent/BR112023021825A2/pt unknown
- 2022-04-22 EP EP22721854.2A patent/EP4326294A1/en active Pending
- 2022-04-22 CA CA3216121A patent/CA3216121A1/en active Pending
- 2022-04-22 US US18/556,827 patent/US20240197787A1/en active Pending
- 2022-04-22 EP EP22724876.2A patent/EP4326295A1/en active Pending
- 2022-04-22 JP JP2023564584A patent/JP2024516173A/ja active Pending
- 2022-04-22 KR KR1020237039592A patent/KR20240001172A/ko active Pending
- 2022-04-22 KR KR1020237039593A patent/KR20240001173A/ko active Pending
- 2022-04-22 WO PCT/IB2022/053763 patent/WO2022224207A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021825A2 (pt) | 2024-02-06 |
| JP2024516173A (ja) | 2024-04-12 |
| US20240197787A1 (en) | 2024-06-20 |
| CA3216129A1 (en) | 2022-10-27 |
| JP2024516172A (ja) | 2024-04-12 |
| WO2022224207A1 (en) | 2022-10-27 |
| EP4326294A1 (en) | 2024-02-28 |
| KR20240001172A (ko) | 2024-01-03 |
| AU2022260822A1 (en) | 2023-11-30 |
| EP4326295A1 (en) | 2024-02-28 |
| KR20240001173A (ko) | 2024-01-03 |
| US20240207323A1 (en) | 2024-06-27 |
| AU2022261504A1 (en) | 2023-11-30 |
| CA3216121A1 (en) | 2022-10-27 |
| WO2022224206A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020042A2 (pt) | Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal | |
| BR112023021840A2 (pt) | Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| BR112022018022A2 (pt) | Método para tratar doença inflamatória intestinal ii | |
| BR112022017557A2 (pt) | Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| BR112022016448A2 (pt) | Método para tratamento de doença do enxerto contra hospedeiro crônica | |
| CO2021002704A2 (es) | Método de producción de precursores neuronales entéricos | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| BR112022017560A2 (pt) | Método para tratar doença inflamatória intestinal i | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| BR112014016950A2 (pt) | métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina | |
| CR20200061A (es) | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) | |
| BR112020010856A8 (pt) | Uso de conjugado de anticorpo anti-her2-fármaco no tratamento de carcinoma urotelial | |
| BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
| BR112016023823A2 (pt) | método para produção de um produto de fermentação | |
| MX2024005253A (es) | Metodos para tratar crecimiento celular anormal. | |
| BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
| BR112022026044A2 (pt) | Tratamento de síndrome do x frágil com canabidiol | |
| BR112022021006A2 (pt) | Métodos para reduzir ou prevenir a colonização de clostridioides difficile | |
| BR112023026559A2 (pt) | Formas cristalinas de trofinetida | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| BR112015017583A2 (pt) | n-metilserotonina e substâncias relacionadas para utilização em tratamento/diminuição da ocorrência de ondas de calor associadas a menopausa | |
| ECSP21040508A (es) | Moduladores de la expresión de foxp3 | |
| SUN | The protective effect of quercetin on vascular endothelial progenitor cells by regulating PI3K/Akt signaling pathway and its mechanisms |